All | Taurolidine | High- concentrated citrate | Low-concentrated citrate | |
---|---|---|---|---|
Number of patients (any CVC, %)a | 1603 | 129 (8) | 1132 (71) | 317 (20) |
Number of CVC in total (%) | 2749 | 211 (8) | 1840 (67) | 490 (18) |
Total number of CVC days (median, IQR) | 271,295 | 40,671 | 166,819 | 43,533 |
Number of proven catheter-related BSI b (%) | 225 | 15 (12) | 149 (13) | 36 (11) |
Incidence rate of BSI per 1000 catheter daysc | 0.83 | 0.37 | 0.89 | 0.83 |
Number of proven catheter-related BSI for femoral CVC (%) | 16 | 2 (10) | 9 (3) | 5 (5) |
Incidence rate of BSI per 1000 catheter days for femoral CVC | 1.77 | 0.80 | 1.70 | 4.03 |
Type of pathogen during BSId | ||||
Coagulase negative staphylococci (%) | 72 (32) | 5 (33) | 46 (31) | 11 (31) |
S. aureus (%) | 61 (27) | 2 (13) | 45 (30) | 9 (25) |
Gram-negative (%) | 43 (19) | 4 (27) | 30 (20) | 6 (17) |
Gram-positive (%) | 40 (18) | 3 (20) | 24 (16) | 9 (25) |
Yeast (%) | 2 (< 1) | – | – | 1 (3) |